Institution
University Psychiatric Hospital
Recent research
- Health & MedicineOpen access
Background Negative symptoms are among the most disabling features of psychotic disorders and frequently persist over time. Baseline clinical measures (e.g. symptom severity at illness onset) explain only part of the variability in long-term outcomes, highlighting the need for im...
- Health & MedicineOpen access
Abstract Background Severe courses of gastrointestinal hypomotility (GIH) are rare but potentially life-threatening adverse drug reactions (ADRs) associated with antipsychotic drugs (APDs). This study aimed to investigate the frequency, clinical characteristics, and associated dr...
- Society & Economics
Introduction Research on music therapy for autistic adults remains limited, particularly regarding how adults experience improvisation-based group therapy. This study explored autistic adults’ lived experiences of participation in a group music therapy programme. To access embodi...
- BiologyOpen access
Abstract Human reward processing varies along cue-centric and outcome-centric axes, but a reproducible mechanistic account of individual variation in incentive salience attribution has been lacking. Using fMRI across five cohorts (N-total=1,251; N1=890; N2=245; N3=34; N4=48; N5=3...
- Health & MedicineOpen access
Abstract Introduction Consensus on essential clinical activities of psychiatric pharmacists is currently unavailable. Agreement on core non-clinical roles relating to research, education, leadership and management is also unavailable. Consensus on the core clinical and non-clinic...
- Health & MedicineOpen access
Molecular Mechanisms of Acute Drug Toxicity in Polypharmacy: Analgesic–Psychotropic Interactions
Concurrent exposure to analgesic and psychotropic drugs is frequent in patients with pain, psychiatric comorbidity, frailty, or acute-care needs. The clinically important question is whether analgesics and psychotropic drugs act on the same metabolic, transporter, receptor, ion-c...
- Health & MedicineOpen access
Anti-amyloid therapy (AAT) with monoclonal antibodies (mAbs) modestly slow cognitive and functional decline in early Alzheimer’s disease (AD). However, both the magnitude of clinical benefit and the risk of treatment-related complications vary substantially even among patients wi...